OXiGENE (OXGN) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OXiGENE Reports First Quarter 2015 Financial Results
April 30, 2015 4:00 PM EDTSOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter ended March 31, 2015.
"We continue to make good progress toward achieving our goals for 2015, which are focused on advancing our pipeline of novel oncology therapeutics," said Dai Chaplin, Ph.D., OXiGENE's President and CEO. "Our clinical programs for fosbretabulin in gastrointestinal neuroendocrine tumors (GI-NETs) and for OXi4503 in acute myeloid leukemia are moving forward as planned. We anticipate receiving definitive regulatory feedback from... More
